ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
Increase of pertussis cases in the Vallès region, Catalonia, Spain, September 2023 to April 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immunogenicity and safety of co-purified diphtheria, tetanus and acellular pertussis vaccine in 6-year-old Chinese children.Nature communications · 2025Trial
- The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative.Infectious diseases and therapy · 2026Review
- Pertussis: a retrospective analysis of cases observed in Mersin Türkiye, 2020 to 2024 evaluation of pertussis cases.BMC infectious diseases · 2026Article
- Global, regional, and national burden of pertussis in children aged 0-14 years from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021.Infectious diseases & immunity · 2026Article
- Bordetella pertussis re-emergence - NGS-based RPTM analysis reveals the atypical clinical features of children.BMC infectious diseases · 2026Article
- Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands.Nature communications · 2026Article
- Pertussis epidemiological surveillance and immunization history in children under five years in a megacity in China from 2019 to 2023.Human vaccines & immunotherapeutics · 2025Article
- Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.BMC infectious diseases · 2025Article
- Bordetella Pertussis in Children: A Retrospective Analysis of the Clinical Impact and the Role of Vaccination.Life (Basel, Switzerland) · 2025Article
- Resurgence ofMicroorganisms · 2025Article
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Article
- Effect of Early Administration of Clarithromycin or Azithromycin on Symptoms of Pertussis in Infants.Antibiotics (Basel, Switzerland) · 2025Article
- Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.Infection & chemotherapy · 2025Review
- Article
- Pertussis resurgence: epidemiological trends, pathogenic mechanisms, and preventive strategies.Frontiers in immunology · 2025Review
- A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge.mSphere · 2024Article
- Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a pertussis outbreak in the Vallès region of Catalonia, from September 2023 to April 2024. Incidence was high in children aged 10-14 years compared with previous outbreaks. Limited impact in newborns could be explained by the high vaccination coverage during pregnancy and at 11 months of age in 2022, at 85% and 94.1 %, respectively. A third booster vaccine dose during preadolescence should be considered and vaccination coverage in pregnant women be improved to control future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.